No increased risk of malformation, miscarriage, stillbirth or neonatal death following mirtazapine use in pregnancy
Researchers based in Denmark have conducted a national population-based comparative cohort study which included between 895 and 1,900 mirtazapine exposed pregnancies (outcome dependent). The results indicated that mirtazapine exposure in pregnancy is not associated with increased risks of major congenital malformation, miscarriage, stillbirth or neonatal death. More details can be found here.
Photo by Ben Blennerhassett on Unsplash